Monoamine Oxidase Inhibitors: A Review of Their Anti-Inflammatory Therapeutic Potential and Mechanisms of Action

Frontiers in Pharmacology, Journal Year: 2021, Volume and Issue: 12

Published: April 30, 2021

Chronic inflammatory diseases are debilitating, affect patients’ quality of life, and a significant financial burden on health care. Inflammation is regulated by pro-inflammatory cytokines chemokines that expressed immune non-immune cells, their expression highly controlled, both spatially temporally. Their dysregulation hallmark chronic autoimmune diseases. Significant evidence supports monoamine oxidase (MAO) inhibitor drugs have anti-inflammatory effects. MAO inhibitors principally prescribed for the management variety central nervous system (CNS)-associated such as depression, Alzheimer’s, Parkinson’s; however, they also effects in CNS non-CNS tissues. To bolster support development anti-inflammatories, it critical to elucidate mechanism(s) action. decrease generation end products hydrogen peroxide, aldehyde, ammonium. They inhibit biogenic amine degradation, this increases cellular pericellular catecholamines some cells. This product metabolites increase can play role inhibitors. review examines inflammation vitro vivo disease models, well

Language: Английский

---

Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors

Health psychology research, Journal Year: 2022, Volume and Issue: 10(4)

Published: Nov. 3, 2022

Monoamine oxidase inhibitors (MAOI) are a class of drugs that were originally developed for the treatment depression but have since been expanded to be used in management affective and neurological disorders, as well stroke aging-related neurocognitive changes. Ranging from irreversible reversible selective non-selective, these target monoamine (MAO) enzyme prevent oxidative deamination various monoamines catecholamines such serotonin dopamine, respectively. Tyramine is potent releaser norepinephrine (NE) found high concentrations foods aged cheeses meats. Under normal conditions, NE unable accumulate toxic levels due presence MAO-A, an degrades neurotransmitters, including NE. When MAO-A inhibited, capacity handle tyramine intake diet significantly reduced causing brain vulnerable overstimulation postsynaptic adrenergic receptors with little 8-10 mg ingested can result life-threatening blood pressure elevations. In addition adverse reactions certain foods, both older newer MAOIs negatively interact sympathomimetic serotonergic drugs. general, patients on MAOI want avoid two types medications: those elevate via actions (e.g., phenylephrine oxymetazoline) increase 5-HT reuptake inhibition dextromethorphan, chlorpheniramine, brompheniramine). Illicit stimulate central nervous system ecstasy (MDMA, 3,4-methylenedioxymethamphetamine) act releasers. Patient involvement also crucial ensure any interaction within healthcare setting includes making other providers aware prescription avoiding OTC medications adversely MAOIs.

Language: Английский

---

The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression

CNS Spectrums, Journal Year: 2022, Volume and Issue: 28(4), P. 427 - 440

Published: July 15, 2022

Abstract This article is a clinical guide which discusses the “state-of-the-art” usage of classic monoamine oxidase inhibitor (MAOI) antidepressants (phenelzine, tranylcypromine, and isocarboxazid) in modern psychiatric practice. The for all clinicians, including those who may not be experienced MAOI prescribers. It indications, drug-drug interactions, side-effect management, safety various augmentation strategies. There clear broad consensus (more than 70 international expert endorsers), based on 6 decades experience, recommendations herein exposited. They are empirical evidence opinion—this presented as new specialist-consensus standard. provides practical advice, basis rational use these drugs, particularly because it improves updates knowledge, corrects misconceptions that have hitherto been prominent literature, partly due to insufficient knowledge pharmacology. suggests MAOIs should always considered cases treatment-resistant depression (including melancholic nature), prior electroconvulsive therapy—while taking into account patient preference. In selected cases, they earlier treatment algorithm has previously customary, regarded drugs last resort; prove decisively effective when many other treatments failed. clarifies key points concomitant incorrectly proscribed such methylphenidate some tricyclic antidepressants. also illustrates straightforward “bridging” methods used transition simply safely from MAOIs.

Language: Английский

---

Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement?

Expert Opinion on Drug Discovery, Journal Year: 2019, Volume and Issue: 14(10), P. 995 - 1035

Published: July 3, 2019

Introduction: Selective monoamine oxidase-B (MAO-B) inhibitors are currently used as coadjuvants for the treatment of early motor symptoms in Parkinson's disease. They can, based on their chemical structure and mechanism inhibition, be categorized into reversible irreversible agents.Areas covered: This review provides a comprehensive update development state selective MAO-B describing results, structures, structure–activity relationships (SARs) Medicinal chemistry strategies well related shortcomings over past five years.Expert opinion: Researchers have explored implemented new old scaffolds achieving high inhibitory potencies isoform selectivity. Most them were characterized proposed multitarget agents able to act at different levels (including AChE H3R or A2AR antagonism, antioxidant chelating properties, Aβ1-42 aggregation reduction) network aetiologies neurodegenerative disorders. These results can also avoid 'cheese-reaction' effects occurrence serotonergic syndrome patients.

Language: Английский

---

Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively

CNS Drugs, Journal Year: 2021, Volume and Issue: 35(7), P. 703 - 716

Published: July 1, 2021

Language: Английский

---

Prescriber's Guide

Published: Nov. 19, 2020

With the range of psychotropic drugs expanding and usages existing medications diversifying, we are pleased to present Seventh Edition world's best-selling formulary in psychopharmacology. The new edition features nine compounds as well information about several formulations drugs. Many important indications covered for drugs, updates profiles entire content collection, including injectable transdermal formulations, updated warnings indications. Pearls have all been refreshed antipsychotics section has completely revised. its easy-to-use, full-colour template-driven navigation system, Prescriber's Guide combines evidence-based data with clinically informed advice support everyone who is prescribing field mental health.

Language: Английский

---

Synthetic cannabinoid receptor agonists are monoamine oxidase‐A selective inhibitors

FEBS Journal, Journal Year: 2023, Volume and Issue: 290(12), P. 3243 - 3257

Published: Jan. 28, 2023

Synthetic cannabinoid receptor agonists (SCRAs) are one of the fastest growing classes recreational drugs. Despite their growth in use, vast chemical diversity and rapidly changing landscape structures make understanding effects challenging. In particular, side for SCRA use extremely diverse, but notably include severe outcomes such as cardiac arrest. These appear at odds with main putative mode action, full receptors. We have hypothesized that SCRAs may act MAO inhibitors, owing to structural similarity known monoamine oxidase inhibitors (MAOI's) well matching clinical (hypertensive crisis) 'monoaminergic toxicity' users MAOIs some use. studied potential SCRA-mediated inhibition MAO-A MAO-B via a range used commonly UK, analogues prove atomistic determinants inhibition. By combining silico experimental kinetic studies we demonstrate MAO-A-specific affinity can vary significantly between SCRAs, most affected by nature 'head' group. Our data allow us posit mechanism Crucially our activity is not limited just agonism alternative interactions might account observed these be SCRA-specific.

Language: Английский

---

Pyrazoline Derivatives as Promising MAO-A Targeting Antidepressants: An Update

Current Topics in Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 24(5), P. 401 - 415

Published: Feb. 1, 2024

Abstract: Depression is one of the key conditions addressed by Mental Health Gap Action Programme (mhGAP) WHO that can lead to self-harm and suicide. associated with low levels neurotransmitters, which eventually play a role in progression development mental illness. The nitrogen-containing heterocyclic compounds exhibit most prominent pharmacological profile as antidepressants. Pyrazoline, dihydro derivative pyrazole, well-known five-membered moiety exhibits broad spectrum biological activities. Many researchers have reported pyrazoline scaffold-containing molecules potential antidepressant agents selectivity for monoamine oxidase enzyme (MAO) isoforms. Several studies indicated better affinity pyrazoline-based (monoamine inhibitors) MAOIs. In this review, we focused on recent advancements (2019-2023) pyrazoline-containing derivatives exhibiting promising inhibition MAO-A treat depression. This review provides structural insights along their SAR analysis, silico exploration binding interactions between enzyme, clinical trial status various drug against in-silico potent at active site MAOA will provide further into new inhibitors treatment

Language: Английский

---

Fermented Soybean Paste Attenuates Biogenic Amine-Induced Liver Damage in Obese Mice

Cells, Journal Year: 2023, Volume and Issue: 12(5), P. 822 - 822

Published: March 6, 2023

Biogenic amines are cellular components produced by the decarboxylation of amino acids; however, excessive biogenic amine production causes adverse health problems. The relationship between hepatic damage and levels in nonalcoholic fatty liver disease (NAFLD) remains unclear. In this study, mice were fed a high-fat diet (HFD) for 10 weeks to induce obesity, presenting early-stage NAFLD. We administered histamine (20 mg/kg) + tyramine (100 via oral gavage 6 days with HFD-induced results showed that combined administration increased cleaved PARP-1 IL-1β liver, as well MAO-A, total MAO, CRP, AST/ALT levels. contrast, survival rate decreased NAFLD mice. Treatment manufactured or traditional fermented soybean paste biogenically elevated expression blood plasma Additionally, amine-induced reduction was alleviated These show can be exacerbated obesity may adversely affect life conservation. However, reduce suggest beneficial effect on provide new research perspective obesity.

Language: Английский

---

Natural deep eutectic solvent-supported exfoliated graphite nanoplatelet-based electrochemical sensor for the determination of tyramine in fermented beverages

Journal of Food Composition and Analysis, Journal Year: 2024, Volume and Issue: 132, P. 106331 - 106331

Published: May 14, 2024

Language: Английский

---